Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma
A phase 1/2 trial of Fludarabine in renal cell carcinoma, run by Beijing Biotech, now recruiting.
Overview
Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma is a phase 1/2 interventional study registered as NCT07551349 by Beijing Biotech, with 36 participants planned, started 2026-02-02 and due to reach its primary completion in 2027-04-14. Interventions recorded: EB-701/CA9-NK, Fludarabine. Conditions listed: Advanced or Metastatic Clear Cell Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.
Setting
An Open-Label, Multicenter, Phase 1/2 Study of Allogeneic Dual-target CD70/CAIX (CA9) Chimeric Antigen Receptor Natural Killer Cells in Adults With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Phase
Phase 1/2
Sponsor
Beijing Biotech
Registry
Enrolled
36